Recovery and Emergence
Adult patients administered ULTANE showed shorter times (statistically significant) to recovery (extubation, response to command, and orientation) than patients who received isoflurane or propofol1,3,4
View the science behind the claims on PubMed
ULTANE is contraindicated in patients with known or suspected genetic susceptibility to malignant hyperthermia or known or suspected sensitivity to sevoflurane or to other halogenated inhalational anesthetics.
In susceptible individuals, volatile anesthetic agents, including sevoflurane, may trigger malignant hyperthermia. Fatal outcomes of malignant hyperthermia have been reported. The risk of developing malignant hyperthermia increases with the concomitant administration of succinylcholine and volatile anesthetic agents. Successful treatment depends on early recognition of the clinical signs. If malignant hyperthermia is suspected, discontinue all triggering agents, administer intravenous dantrolene sodium, and initiate supportive therapies.
Adverse events reported by ≥5% of the surgical patients receiving ULTANE during clinical trials during induction included: bradycardia, tachycardia, agitation, laryngospasm, airway obstruction, breathholding, and increased cough; during maintenance and emergence: shivering, hypotension, bradycardia, somnolence, agitation, nausea, vomiting, and increased cough were reported.